Radiopharmaceutical therapy (RPT) is advancing rapidly and achieving wider clinical application. However, RPT is not yet optimized in practice, as tumor and normal-organ dose estimates and, in turn, dose-response relationships remain poorly defined. Internal dosimetry is evolving to address such issues, transitioning from the estimation of population-average organ-level or tumor-level doses to individualized patient-specific sub-organ or sub-tumor doses. Derivation of patient-specific doses allows the further development of reliable dose-response relationships for diseased tissues and dose-toxicity relationships for normal tissues. Resources such as commercially available or publicly downloadable software are being increasingly developed to facilitate the use of these emerging methods. This review addresses the determination of patient-specific radiation doses for target tissue and at-risk normal tissues in the setting of RPT. Topics covered include: quantities, units, and radionuclides relevant to RPT; dose prescription algorithms; the steps in the dosimetry workflow; and bioeffects modeling. Implementation of patient-specific dosimetry will be essential for this therapeutic modality's optimization and further clinical expansion.

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.24.31873DOI Listing

Publication Analysis

Top Keywords

radiopharmaceutical therapy
8
dose-response relationships
8
normal tissues
8
dosimetry
4
dosimetry radiopharmaceutical
4
therapy practical
4
practical implementation
4
implementation special
4
special series
4
series quantitative
4

Similar Publications

Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile. Semaglutide may have a disease-modifying, neuroprotective effect in AD through multimodal mechanisms including neuroinflammatory, vascular, and other AD-related processes.

View Article and Find Full Text PDF

Development of Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging.

Mol Pharm

January 2025

Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.

As an enzyme that plays an important role in DNA repair, poly(ADP-ribose) polymerase-1 (PARP-1) has become a popular target for cancer therapy. Nuclear medicine molecular imaging technology, supplemented by radiolabeled PARP-1 inhibitors, can accurately determine the expression level of PARP-1 at lesion sites to help patients choose an appropriate treatment plan. In this work, niraparib was modified with a hydrazinonicotinamide (HYNIC) group to generate the ligand NPBHYNIC, which has an affinity (IC) of 450.

View Article and Find Full Text PDF

Dosimetry is integral to informed implementation of radiopharmaceutical therapies, enabling personalized treatment planning and ensuring patient safety by calculating absorbed doses to organs and tumors. As the therapeutic radiopharmaceutical field continues to expand, dosimetry software has emerged as a crucial tool for optimization of treatment efficacy. This review discusses key features and capabilities that current dosimetry software solutions have or should have in the future.

View Article and Find Full Text PDF

Monitoring of cancer ferroptosis with [F]hGTS13, a system xc- specific radiotracer.

Theranostics

January 2025

Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, CA, 94305, USA.

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults, characterized by resistance to conventional therapies and poor survival. Ferroptosis, a form of regulated cell death driven by lipid peroxidation, has recently emerged as a promising therapeutic target for GBM treatment. However, there are currently no non-invasive imaging techniques to monitor the engagement of pro-ferroptotic compounds with their respective targets, or to monitor the efficacy of ferroptosis-based therapies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!